Grant of Share Option & Total Voting Rights

RNS Number : 2831E

Venn Life Sciences Holdings PLC

03 November 2015

 

3 November 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Grant of Share Option

& Total Voting Rights

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that it has granted an option over 770,000 ordinary shares, representing 1.28% of the current issued share capital of the Company, to Jonathan Hartshorn, Chief Financial Officer.

The shares have an exercise price of 23p, and an exercise period from 3 November 2018 to 2 November 2025.

Following this grant the Company has granted options over 3,640,000 ordinary representing 6.04% of the current issued share capital.

Total Voting Rights

The Company's issued share capital consists of 60,239,263 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that the total number of voting rights in the Company are 60,239,263.

Enquiries:

Venn Life Sciences Holdings Plc		www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Jonathan Hartshorn, Chief Financial Officer		Tel: [phone]
Orla McGuinness, Marketing Manager		Tel: [phone]
Zeus Capital (Nominated Adviser and Co-Broker)
Andrew Jones/Phil Walker		Tel: [phone]
Dominic Wilson/Alex Davies		Tel : [phone]
Hybridan LLP (Co-Broker)
Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus		Mob: [phone]
Lianne Cawthorne		Mob: [phone]

About Venn Life Sciences Limited:

Venn is a full service European Contract Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation, Venn specialises in both national and European-wide Phase II-Phase IV multi-site trials with extensive expertise in EU regulations, therapeutic areas and local languages. Over a 25 year history, Venn has built up substantial study experience, contributing to the efficient management of sites, budgets and communication channels with all parties involved. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. In October 2015 Venn completed the acquisition of Kinesis Pharma BV, highly differentiating Venn within the CRO market as it can now offer services from early clinical/non-clinical evaluation through to Phase IV. This deepens its service capability and enables Venn to offer a complete end-to-end service.

 

 

END

 

 

MSCUUVNRVNAARAA